Home  »  Business   »  Looking Closely at the Growth Curve for Mersana Th...

Looking Closely at the Growth Curve for Mersana Therapeutics Inc. (MRSN)

Mersana Therapeutics Inc. (NASDAQ:MRSN) went up by 9.97% from its latest closing price compared to the recent 1-year high of $8.34. The company’s stock price has collected 0.79% of gains in the last five trading sessions.

Is It Worth Investing in Mersana Therapeutics Inc. (NASDAQ :MRSN) Right Now?

Plus, the 36-month beta value for MRSN is at 1.71. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Mersana Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


The average price from analysts is $16.83, which is $11.4 above the current price. MRSN currently public float of 98.80M and currently shorts hold a 5.11% ratio of that float. Today, the average trading volume of MRSN was 1.08M shares.

MRSN’s Market Performance

MRSN stocks went up by 0.79% for the week, with a monthly jump of 12.48% and a quarterly performance of -4.62%, while its annual performance rate touched 13.07%. The volatility ratio for the week stands at 7.34% while the volatility levels for the past 30 days are set at 7.43% for Mersana Therapeutics Inc. The simple moving average for the period of the last 20 days is 10.99% for MRSN stocks with a simple moving average of 12.34% for the last 200 days.

Analysts’ Opinion of MRSN

Many brokerage firms have already submitted their reports for MRSN stocks, with Citigroup repeating the rating for MRSN by listing it as a “Buy.” The predicted price for MRSN in the upcoming period, according to Citigroup is $12 based on the research report published on January 20th of the current year 2023.

Truist, on the other hand, stated in their research note that they expect to see MRSN reach a price target of $12. The rating they have provided for MRSN stocks is “Buy” according to the report published on November 21st, 2022.

BTIG Research gave a rating of “Buy” to MRSN, setting the target price at $32 in the report published on October 15th of the previous year.

MRSN Trading at 1.44% from the 50-Day Moving Average

After a stumble in the market that brought MRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.24% of loss for the given period.

Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 7.34%, as shares surge +6.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.61% lower at present.

During the last 5 trading sessions, MRSN rose by +0.79%, which changed the moving average for the period of 200-days by +40.97% in comparison to the 20-day moving average, which settled at $5.79. In addition, Mersana Therapeutics Inc. saw 9.22% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MRSN starting from Yang Arvin, who sale 2,209 shares at the price of $5.74 back on Jan 17. After this action, Yang Arvin now owns 30,821 shares of Mersana Therapeutics Inc., valued at $12,680 using the latest closing price.

Protopapas Anna, the President & CEO of Mersana Therapeutics Inc., sale 17,346 shares at $5.74 during a trade that took place back on Jan 17, which means that Protopapas Anna is holding 48,733 shares at $99,566 based on the most recent closing price.

Stock Fundamentals for MRSN

Current profitability levels for the company are sitting at:

  • -392693.02 for the present operating margin

The net margin for Mersana Therapeutics Inc. stands at -395488.37. Equity return is now at value -171.20, with -80.80 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.97.

Is Sprout Social Inc. (SPT) a Keeper?

Sprout Social Inc. (NASDAQ:SPT) went up by 10.18% from its latest closing price compared to the recent 1-year high of $85.99. The company’s stock price